{"id":"itopride","rwe":[],"tags":[{"label":"itopride","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A03FA07","category":"atc"},{"label":"Active","category":"status"},{"label":"Chronic gastritis","category":"indication"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":180.756,"date":"","count":22,"signal":"Trimethylaminuria","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=181)"},{"llr":99.15,"date":"","count":21,"signal":"Pseudomembranous colitis","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=99)"},{"llr":92.281,"date":"","count":16,"signal":"Dysbiosis","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=92)"},{"llr":89.954,"date":"","count":18,"signal":"Megacolon","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=90)"},{"llr":84.621,"date":"","count":26,"signal":"Peritonitis","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=85)"},{"llr":72.277,"date":"","count":21,"signal":"Intestinal perforation","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=72)"},{"llr":52.963,"date":"","count":43,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 43 times (LLR=53)"},{"llr":52.596,"date":"","count":12,"signal":"Inhibitory drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=53)"},{"llr":51.625,"date":"","count":20,"signal":"Clostridium difficile infection","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=52)"},{"llr":43.032,"date":"","count":9,"signal":"Breath odour","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=43)"},{"llr":42.005,"date":"","count":11,"signal":"Urine odour abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=42)"},{"llr":41.196,"date":"","count":11,"signal":"Bacterial test positive","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=41)"},{"llr":38.483,"date":"","count":10,"signal":"White blood cells urine positive","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=38)"}],"commonSideEffects":[{"effect":"Diarrhoea","drugRate":"5.7%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":16,"trialsReporting":1},{"effect":"Dizziness","drugRate":"2.9%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":280,"totalAffected":8,"trialsReporting":1},{"effect":"Headache","drugRate":"2.1%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":280,"totalAffected":6,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"1.8%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":5,"trialsReporting":1},{"effect":"Nausea","drugRate":"1.8%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":5,"trialsReporting":1},{"effect":"Abdominal pain upper","drugRate":"1.1%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":3,"trialsReporting":1},{"effect":"Influenza","drugRate":"1.1%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":280,"totalAffected":3,"trialsReporting":1},{"effect":"Dyspnoea","drugRate":"1.1%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":3,"trialsReporting":1},{"effect":"Hypertension","drugRate":"1.1%","organSystem":"Vascular disorders","placeboRate":"","totalAtRisk":280,"totalAffected":3,"trialsReporting":1},{"effect":"Abdominal discomfort","drugRate":"0.7%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":2,"trialsReporting":1},{"effect":"Anal fissure","drugRate":"0.7%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":2,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"0.7%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":2,"trialsReporting":1},{"effect":"Rhinitis allergic","drugRate":"0.7%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":2,"trialsReporting":1},{"effect":"Acne","drugRate":"0.7%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":280,"totalAffected":2,"trialsReporting":1},{"effect":"Dyspepsia","drugRate":"0.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Epigastric discomfort","drugRate":"0.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Toothache","drugRate":"0.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Gastrointestinal disorder","drugRate":"0.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Irritable bowel syndrome","drugRate":"0.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Laryngitis","drugRate":"0.4%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Pharyngotonsillitis","drugRate":"0.4%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Systemic viral infection","drugRate":"0.4%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Tracheobronchitis viral","drugRate":"0.4%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Gastroenteritis","drugRate":"0.4%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Conjunctivitis","drugRate":"0.4%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Otitis media","drugRate":"0.4%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Hypertonia","drugRate":"0.4%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Asphyxia","drugRate":"0.4%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Cough","drugRate":"0.4%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Oropharyngeal pain","drugRate":"0.4%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Asthma","drugRate":"0.4%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Laryngeal oedema","drugRate":"0.4%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Dyslipidaemia","drugRate":"0.4%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Type 2 diabetes mellitus","drugRate":"0.4%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"0.4%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Costochondritis","drugRate":"0.4%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Intervertebral disc protrusion","drugRate":"0.4%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"0.4%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Myalgia","drugRate":"0.4%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"0.4%","organSystem":"General disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Early satiety","drugRate":"0.4%","organSystem":"General disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Face oedema","drugRate":"0.4%","organSystem":"General disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Palpitations","drugRate":"0.4%","organSystem":"Cardiac disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Tachycardia","drugRate":"0.4%","organSystem":"Cardiac disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Hyperprolactinaemia","drugRate":"0.4%","organSystem":"Endocrine disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Aspartate aminotransferase increased","drugRate":"0.4%","organSystem":"Investigations","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Heart rate decreased","drugRate":"0.4%","organSystem":"Investigations","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Anaemia","drugRate":"0.4%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Confusional state","drugRate":"0.4%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1},{"effect":"Insomnia","drugRate":"0.4%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":280,"totalAffected":1,"trialsReporting":1}],"seriousAdverseEvents":[{"event":"Urinary tract infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Pulmonary embolism","detail":"Respiratory, thoracic and mediastinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:40:02.089501+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:57:13.104093+00:00"}},"allNames":"ganaton","offLabel":[],"synonyms":["itopride hydrochloride","ganaton","itopride","itropride","itopride HCl"],"timeline":[],"approvals":[],"brandName":"Ganaton","ecosystem":[{"indication":"Chronic gastritis","otherDrugs":[],"globalPrevalence":159000000}],"mechanism":{"modality":"Small Molecule","drugClass":"itopride","explanation":"Think of it like a key that unlocks the stomach's digestive machinery. Acetylcholine is a natural chemical that helps to stimulate the muscles in the stomach to move food along and help with digestion. By increasing the release of acetylcholine, itopride helps to improve the stomach's ability to digest food and reduce inflammation.","oneSentence":"Itopride works by increasing the release of a natural chemical called acetylcholine in the stomach, which helps to stimulate digestive processes.","technicalDetail":"Itopride acts as a selective M3 muscarinic receptor agonist, which enhances the release of acetylcholine from the enteric nervous system, thereby stimulating gastrointestinal motility and secretory functions."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Itopride","title":"Itopride","extract":"Itopride (INN; brand name Ganaton) is a prokinetic benzamide derivative. These drugs inhibit dopamine and acetylcholine esterase enzyme and have a gastrokinetic effect. Itopride is indicated for the treatment of functional dyspepsia and other gastrointestinal conditions. It is a combined D2 receptor antagonist and acetylcholinesterase inhibitor. Itopride is the dimethoxy analog of trimethobenzamide.","wiki_society_and_culture":"== Society and culture ==\n===Names===\nItopride is available under various brand names including Ganaton (Japan, India, Czech Republic, Russian Federation), Itoprid PMCS (Czech Republic, Slovakia), Itomed (Kyrgyzstan, Kazakhstan, Moldova, Russia, Ukraine, Uzbekistan), Prokit (Poland), and Itogard (Nepal). In Mexico, itopride is sold by Takeda Laboratories under the brand name Dagla. In Bulgaria and other countries of East Europe itopride is sold by Zentiva under the brand name Zirid"},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1512","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ITOPRIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ITOPRIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Itopride","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T12:12:08.692650","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:40:09.400038+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"metoclopramide","drugSlug":"metoclopramide","fdaApproval":"1979-02-07","patentExpiry":"Nov 17, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cisapride","drugSlug":"cisapride","fdaApproval":"1993-07-29","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"itopride","indications":{"approved":[{"name":"Chronic gastritis","source":"DrugCentral","snomedId":8493009,"regulator":"FDA","globalPrevalence":159000000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Microb Pathog, 2022 (PMID:35405277)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"metoclopramide","brandName":"metoclopramide","genericName":"metoclopramide","approvalYear":"1979","relationship":"same-class"},{"drugId":"cisapride","brandName":"cisapride","genericName":"cisapride","approvalYear":"1993","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07449689","phase":"PHASE4","title":"Comparing Acotiamide and Itopride for the Management of Indigestion","status":"NOT_YET_RECRUITING","sponsor":"Aga Khan University","startDate":"2026-04","conditions":["Functioanl Dyspepsia","Post Prandial Distress Syndrome"],"enrollment":368,"completionDate":"2027-05"},{"nctId":"NCT07254715","phase":"PHASE4","title":"Effect of Itopride on Semaglutide Gastroparesis","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-12","conditions":["Semaglutide-Induced Gastric Motility","Anesthesia"],"enrollment":60,"completionDate":"2026-04"},{"nctId":"NCT07174297","phase":"PHASE3","title":"Acotiamide vs Itopride in Postprandial Distress Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Getz Pharma","startDate":"2025-10-30","conditions":["Postprandial Distress Syndrome"],"enrollment":152,"completionDate":"2027-04-30"},{"nctId":"NCT07165301","phase":"","title":"Postprandial Distress Itopride Cohort Trial","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-10","conditions":["Postprandial Distress Syndrome","Functional Dyspepsia","Epigastric Pain Syndrome"],"enrollment":200,"completionDate":"2026-07-31"},{"nctId":"NCT07031479","phase":"PHASE4","title":"Efficacy of Itopride Versus Metoclopramide in Hospitalized Medicine Patients With High Gastric Residual Volume","status":"NOT_YET_RECRUITING","sponsor":"Chulalongkorn University","startDate":"2025-07-01","conditions":["Feeding Intolerance"],"enrollment":86,"completionDate":"2026-09-30"},{"nctId":"NCT06217393","phase":"PHASE3","title":"Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott","startDate":"2024-02-28","conditions":["Functional Dyspepsia"],"enrollment":564,"completionDate":"2025-02-28"},{"nctId":"NCT06559748","phase":"","title":"A Trial of Transcranial Magnetic Stimulation in the Treatment of Functional Dyspepsia","status":"TEMPORARILY_NOT_AVAILABLE","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"","conditions":["Functional Dysphonia"],"enrollment":0,"completionDate":""},{"nctId":"NCT05966025","phase":"PHASE2","title":"Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)","status":"UNKNOWN","sponsor":"October 6 University","startDate":"2023-12-28","conditions":["Fatty Liver Disease","Fatty Liver"],"enrollment":60,"completionDate":"2025-12"},{"nctId":"NCT04918017","phase":"PHASE4","title":"Treatment Outcomes For Functional Dyspepsia Based On Current International Guidelines In Multi-Ethnic Asian Patients","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2021-11-18","conditions":["Functional Dyspepsia"],"enrollment":180,"completionDate":"2023-12-31"},{"nctId":"NCT05134584","phase":"PHASE4","title":"Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2021-01-01","conditions":["Functional Dyspepsia","Constipation-predominant Irritable Bowel Syndrome"],"enrollment":78,"completionDate":"2022-02"},{"nctId":"NCT04104867","phase":"NA","title":"Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2019-09-16","conditions":["Abdominal Pain"],"enrollment":525,"completionDate":"2023-02-01"},{"nctId":"NCT04697641","phase":"NA","title":"Helicobacter Pylori Eradication in Functional Dyspepsia","status":"COMPLETED","sponsor":"Sir Ganga Ram Hospital","startDate":"2017-09-01","conditions":["Dyspepsia","Helicobacter Pylori Infection"],"enrollment":202,"completionDate":"2019-05-31"},{"nctId":"NCT04647955","phase":"PHASE4","title":"Functional Dyspepsia: Validation of a Questionnaire for Symptom Assessment in FD PDS Subgroup","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-02-22","conditions":["Functional Dyspepsia","Postprandial Fullness Syndrome"],"enrollment":100,"completionDate":"2015-10"},{"nctId":"NCT04572932","phase":"NA","title":"Probiotics and Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-05-01","conditions":["Irritable Bowel Syndrome"],"enrollment":90,"completionDate":"2020-02-29"},{"nctId":"NCT04464369","phase":"PHASE4","title":"Functional Dyspepsia: Validation of the Leuven Postprandial Distress Scale (LPDS) in a Placebo-controlled Trial","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-09","conditions":["Functional Dyspepsia"],"enrollment":105,"completionDate":"2016-11"},{"nctId":"NCT04161768","phase":"PHASE3","title":"Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2018-12-01","conditions":["Spontaneous Bacterial Peritonitis"],"enrollment":80,"completionDate":"2028-12-01"},{"nctId":"NCT03698292","phase":"NA","title":"Itopride in Feeding Intolerance of Critically-ill Patients Receiving Enteral Nutrition","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2018-10","conditions":["Critically-ill Patients"],"enrollment":60,"completionDate":"2019-09"},{"nctId":"NCT00370084","phase":"PHASE1,PHASE2","title":"Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2005-03","conditions":["Gastroparesis"],"enrollment":25,"completionDate":"2006-07"},{"nctId":"NCT00370110","phase":"PHASE1,PHASE2","title":"Effects of Itopride on Gastric Motor and Sensory Functions in Healthy Volunteers","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2005-08","conditions":["Healthy"],"enrollment":45,"completionDate":"2005-11"},{"nctId":"NCT00382577","phase":"PHASE3","title":"Efficacy and Safety of Itopride vs Placebo in Heartburn","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2006-10","conditions":["Heartburn"],"enrollment":48,"completionDate":"2006-12"},{"nctId":"NCT00112190","phase":"PHASE3","title":"Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2004-07","conditions":["Dyspepsia"],"enrollment":645,"completionDate":"2006-03"},{"nctId":"NCT00112177","phase":"PHASE3","title":"Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2004-07","conditions":["Dyspepsia"],"enrollment":500,"completionDate":"2006-08"},{"nctId":"NCT00112203","phase":"PHASE3","title":"Long-Term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2004-11","conditions":["Dyspepsia"],"enrollment":466,"completionDate":"2006-09"},{"nctId":"NCT00110968","phase":"PHASE3","title":"Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2004-09","conditions":["Dyspepsia"],"enrollment":300,"completionDate":"2006-09"},{"nctId":"NCT01332890","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2011-04","conditions":["Healthy"],"enrollment":30,"completionDate":"2011-08"},{"nctId":"NCT01027260","phase":"PHASE2","title":"Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-06","conditions":["Irritable Bowel Syndrome"],"enrollment":268,"completionDate":"2010-09"},{"nctId":"NCT01513811","phase":"PHASE2","title":"Itopride as an Adjuvant for Bowel Preparation in Patients With Chronic Constipation is Effective","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2010-02","conditions":["Constipation"],"enrollment":115,"completionDate":"2011-12"},{"nctId":"NCT01513096","phase":"PHASE3","title":"Efficacy of Prokinetics With Split Dose of PEG in Morning Colonoscopic Bowel Preparation","status":"COMPLETED","sponsor":"Inje University","startDate":"2011-11","conditions":["Colonoscopy","Bowel Preparation"],"enrollment":152,"completionDate":"2012-01"},{"nctId":"NCT00599677","phase":"NA","title":"Randomized Controlled Trial of Acupuncture for Functional Dyspepsia","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2007-11","conditions":["Functional Dyspepsia"],"enrollment":720,"completionDate":"2009-09"},{"nctId":"NCT00308399","phase":"PHASE2,PHASE3","title":"A Study to Evaluate the Effect of a Medicine on Gastric Functions in Healthy Volunteers.","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-11","conditions":["Healthy Volunteers"],"enrollment":45,"completionDate":"2007-06"},{"nctId":"NCT01226134","phase":"NA","title":"Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2009-02","conditions":["Functional Dyspepsia","Gastric Emptying","Gastric Accommodation"],"enrollment":30,"completionDate":"2011-05"},{"nctId":"NCT00272103","phase":"PHASE2,PHASE3","title":"Itopride in Functional Dyspepsia:a Dose Finding Study","status":"COMPLETED","sponsor":"Royal Adelaide Hospital","startDate":"2000-12","conditions":["Functional Dyspepsia"],"enrollment":500,"completionDate":"2002-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"017624","UNII":"81BMQ80QRL","CHEBI":"CHEBI:94809","INN_ID":"6879","UMLSCUI":"C0531483","ChEMBL_ID":"CHEMBL2107457","KEGG_DRUG":"D02729","DRUGBANK_ID":"DB04924","PUBCHEM_CID":"3792","SNOMEDCT_US":"1217454005","SECONDARY_CAS_RN":"122892-31-3","MESH_SUPPLEMENTAL_RECORD_UI":"C102254"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":178,"therapeuticAreas":["Gastroenterology"],"atcClassification":{"source":"DrugCentral","atcCode":"A03FA07","allCodes":["A03FA07"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:40:09.400038+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}